Collaborating
OncoOne is collaborating with outstanding partners to propel pioneering treatments forward through flexible scientific approaches, swiftly bringing precision medicines to those in need. Our goal is to have top talent engaged in cutting-edge research, necessitating the identification and cultivation of exceptional partnerships. If you are interested in partnering with us, please fill out our contact form.
Our Current Partners
Assistant Professor George Lisi and his team at Brown University specialize in studying protein structural regulation in various diseases. Utilizing advanced biophysical and biochemical tools, the team analyses enzyme structures and explores the picosecond-to-second dynamics that propagate mechanistically important biological signals. Our joint efforts aim to uncover the structure-dependent pathological properties of oxMIF using cutting-edge biophysical methods.
Dr. John Heymach is the Chair of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA. Together with Dr. Heymach, based on an MTA, we are exploring the effectiveness of our innovative anti-oxMIF therapeutic antibody, ON203, in in vivo models of non-small cell lung cancer (NSCLC).
Assistant Professor George Lisi and his team at Brown University specialize in studying protein structural regulation in various diseases. Utilizing advanced biophysical and biochemical tools, the team analyses enzyme structures and explores the picosecond-to-second dynamics that propagate mechanistically important biological signals. Our joint efforts aim to uncover the structure-dependent pathological properties of oxMIF using cutting-edge biophysical methods.
Dr. John Heymach is the Chair of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA. Together with Dr. Heymach, based on an MTA, we are exploring the effectiveness of our innovative anti-oxMIF therapeutic antibody, ON203, in in vivo models of non-small cell lung cancer (NSCLC).
Professor Nicoletti, affiliated with the University of Catania, is a prominent authority in MIF research, recognized worldwide for expertise in preclinical models related to immunoinflammatory and autoimmune diseases and cancer. Leveraging a robust background in developing in vivo animal models of inflammation, our collaboration with Professor Nicoletti's team will delve into exploring the anti-inflammatory potential of OncoOne’s anti-oxMIF antibodies in arthritis and colitis models.
Professor Tam's research at Imperial College London delves into the role of cytokines in glomerulonephritis, diabetic nephropathy, and renal allograft rejection. Together with his team, he pioneers experimental therapies for glomerulonephritis, employing innovative approaches like soluble cytokine receptors, antagonists, and monoclonal antibodies. Leveraging their expertise, they closely collaborate with OncoOne to exploring the therapeutic efficacy of anti-oxMIF antibodies in experimental glomerulonephritis.
Professor Nicoletti, affiliated with the University of Catania, is a prominent authority in MIF research, recognized worldwide for expertise in preclinical models related to immunoinflammatory and autoimmune diseases and cancer. Leveraging a robust background in developing in vivo animal models of inflammation, our collaboration with Professor Nicoletti's team will delve into exploring the anti-inflammatory potential of OncoOne’s anti-oxMIF antibodies in arthritis and colitis models.
Professor Tam's research at Imperial College London delves into the role of cytokines in glomerulonephritis, diabetic nephropathy, and renal allograft rejection. Together with his team, he pioneers experimental therapies for glomerulonephritis, employing innovative approaches like soluble cytokine receptors, antagonists, and monoclonal antibodies. Leveraging their expertise, they closely collaborate with OncoOne to exploring the therapeutic efficacy of anti-oxMIF antibodies in experimental glomerulonephritis.
Adgyl Life Science provides comprehensive services for Discovery, Preclinical, and Early Clinical development programs, ensuring safety assessment and global regulatory compliance. With over 30 years of GLP experience, Adgyl guarantees the highest data quality and reliability. They are our trusted partner for pharmacokinetic and toxicology studies, advancing our therapeutic monoclonal antibodies to clinical trials.
GenScript ProBio, a premier global CDMO, accelerates the drug development journey from discovery to commercialization with its holistic solutions and efficient biologic processes. Their integrated DNA to GMP platform includes cell line development, commercial licensing, and both process and analytical development, leading up to clinical and commercial manufacturing. In November 2021, OncoOne partnered with GenScript ProBio to produce our monoclonal antibodies targeting oxMIF.
Adgyl Life Science provides comprehensive services for Discovery, Preclinical, and Early Clinical development programs, ensuring safety assessment and global regulatory compliance. With over 30 years of GLP experience, Adgyl guarantees the highest data quality and reliability. They are our trusted partner for pharmacokinetic and toxicology studies, advancing our therapeutic monoclonal antibodies to clinical trials.
GenScript ProBio, a premier global CDMO, accelerates the drug development journey from discovery to commercialization with its holistic solutions and efficient biologic processes. Their integrated DNA to GMP platform includes cell line development, commercial licensing, and both process and analytical development, leading up to clinical and commercial manufacturing. In November 2021, OncoOne partnered with GenScript ProBio to produce our monoclonal antibodies targeting oxMIF.
